Reunite dual-chamber cartridge autoinjector datasheet

SHL Medical is pleased to announce two significant construction milestones that highlight the momentum of the organization’s global expansion. Both the new manufacturing facilities in Zug, Switzerland, and the Taoyuan-Nanmei in Taiwan have reached their topping-out stages, marking major progress on two cornerstone sites that will strengthen SHL Medical’s long-term operational capabilities. 

From design to mass production, SHL Medical's end-to-end device development infrastructure ensures the lasting value of self-injection systems that we design and develop with our customers. Our comprehensive in-house manufacturing capabilities and expertise include every core competency and value-added services across the product lifecycle. 35 years of pioneering the drug delivery industryOver 50 combination products launchedTop 25 bio/pharmaceutical companies in partnership Over 120M SHL devices reached patients worldwide

First look at a new solution for cardiometabolic drug delivery

A retrospective analysis on how the new generation of Molly autoinjectors have incorporated a greater level of flexibility in its design and development model.

SHL Medical is proud to announce that three of its production facilities in Taiwan have been awarded the ISCC Plus certification for bio-based and circular materials. This accomplishment marks a significant advancement in SHL Medical’s sustainability roadmap and strengthens its ability to develop eco-designed drug-delivery devices.

Maggie 5.0 mL is the large-volume variation of the Maggie cartridge-based autoinjector, built with SHL’s market-proven Needle Isolation Technology (NIT). Maggie accommodates a wider variety of formulation characteristics and volumes that are not possible with pre-filled syringe-based autoinjectors.

SHL Medical is proud to support a transformative initiative led by ChildFund International, Barnfonden, and Swedish greentech company Spowdi, aimed at empowering small-hold farmers in Kenya.

Maggie is a cartridge-based autoinjector technology built with our market-proven Needle Isolation Technology (NIT). Maggie accommodates a wider variety of formulation characteristics and volumes that are not possible with pre-filled syringe-based autoinjectors.

Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector. 

Molly 2.25 is a large-volume variant of the Molly autoinjector to accommodate larger-volume biologics. Featuring the same easy-to-use, 2-step operation, it inherited the modular platform development model to support high-volume manufacturing, faster development, and flexible design for unique branding needs. 

Within its alliance partnership framework, SHL Medical, a world-leading solutions provider of advanced drug delivery systems has entered a non-exclusive strategic partnership with Lyophilization Technology, Inc. (hereafter “LTI”), a contract development and manufacturing organization (CDMO) specializing in lyophilization for preparation of health care products.

Molly is a single-dose autoinjector technology developed to help pharma and biotech companies reduce initial investments and expedite development timelines. Built on a modular platform technology, Molly is designed to meet the evolving requirements of future autoinjectors, such as introducing unique designs for branding and user requirements, as well as high-volume manufacturing. 

The Molly autoinjector is designed with an ergonomic body and a flange-shaped anti-roll cap for an easier handling experience.

With 1.5 billion autoinjectors shipped worldwide, SHL Medical celebrates a significant milestone in our journey to enable patients’ independence. This achievement reflects both the scale of our global impact and the trust placed in us by pharmaceutical and biotech partners who continue to inspire our innovation in drug delivery. 

Elexy is a versatile, electromechanical autoinjector with a reusable power unit compatible with drug cassettes containing a pre-filled syringe or cartridge.

Elexy aims to provide a best-in-class user experience and a wide range of injection profiles. Comprised of a reusable power unit and disposable drug cassettes, the Elexy system is compatible with both pre-filled syringe (PFS) and cartridge primary containers and, capable of delivering up to 5.0 mL in a single injection.

SHL Medical has announced the debut of its Reunite™ autoinjector, a dual-chamber cartridge-based device featuring the company’s proprietary Needle Isolation Technology (NIT®). Reunite is designed to simplify the automated reconstitution and delivery of lyophilized formulations, addressing the complexities and risks of traditional vial-kit preparation.

With just three steps—unlock, twist, push—Reunite makes lyophilized drug administration as straightforward as using a standard autoinjector. Built with SHL’s proven NIT, the device eliminates manual needle attachment while providing full control over cannula gauge and length to support target injection time and depth.

This introduction underscores SHL’s continued leadership in advancing patient-friendly drug delivery solutions and its commitment to enabling reliable self-injection options for complex biologics.

Elexy is a versatile, electromechanical autoinjector with a reusable power unit compatible with drug cassettes containing a pre-filled syringe or cartridge.

Elexy aims to provide a best-in-class user experience and a wide range of injection profiles. Comprised of a reusable power unit and disposable drug cassettes, the Elexy system is compatible with both pre-filled syringe (PFS) and cartridge primary containers and, capable of delivering up to 5.0 mL in a single injection.

SHL Medical has announced the commercial launch of its Molly® autoinjector platform for Pyzchiva®, the first ustekinumab biosimilar autoinjector available in Europe, developed by Samsung Bioepis and commercialized by Sandoz. This milestone highlights the success of their strategic collaboration and reinforces Molly’s role in delivering therapies for chronic inflammatory conditions.

With 21 approved combination products across 28+ indications, Molly is one of the most widely adopted autoinjector platforms, supporting treatments for autoimmune diseases, metabolic disorders, and obesity. Its modular design helps reduce development risk and accelerate time-to-market.

This latest launch underscores SHL’s commitment to patient independence and its leadership in partnering with pharma companies to bring self-injection solutions to market efficiently and reliably.

Device component manufacturers play a critical role in meeting both syringe-level and end-to-end system performance requirements. By aligning early on materials, tolerances, and functional testing, pharma teams can reduce risk, improve integration, and accelerate development from component selection through final device performance validation.

SHL Medical has released its 2024 Sustainability Report, highlighting its ongoing commitment to environmental stewardship, social responsibility, and responsible growth. The report details the company’s efforts to integrate sustainability into its innovation, operations, and global patient access strategy.

Sustainability is embedded in SHL’s core business practices, supporting resilience, operational excellence, and alignment with customer needs. The report outlines progress on reducing emissions, advancing eco-design, and strengthening corporate governance.

Prepared in line with Global Reporting Initiative (GRI) Standards, the report reflects SHL’s transparent and proactive approach to sustainability across its value chain.

In this presentation, we introduce our most recent development – a versatile, reusable, and connected electromechanical solution that upholds the concept of drug agnosticism, platform flexibility, ease-of-use, as well as device programmability. By leveraging technological application expertise, we demonstrate how an electromechanical, versatile device platform can flexibly host different primary containers and formulations. 

SHL Medical is expanding its presence in Shanghai as part of its global growth strategy, aiming to become the market leader in China’s rapidly growing autoinjector sector by the end of 2025. With a current 49% market share and nearly 8 million devices sold, SHL plans to leverage its regulatory expertise, IP portfolio, and successful launch history to deepen customer relationships and attract new partners.

The new office, located in Zhangjiang Hi-Tech Park in Pudong, will serve as a key business development hub. SHL will showcase its self-injection solutions and local team at CPhI China, taking place June 24–26, 2025.

Digital health solutions create myriad possibilities in terms of enabling “beyond the pill” health outcomes. However, the path to streamlining a strategic approach between pharma and its development partners toward creating smart combination products remains a challenge. With a general consensus that developers must accurately determine in advance what users want, many companies wait upon the success of early players as a determinant to foray into digital health. This philosophy, however, disregards the heterogeneity of combination products in development along with the diversity of clinical or patient-reported outcomes measures. Here, we present a dissection of SHL Medical’s Innovation Partnership program along with our connected device offering – both of which allows us to flexibly collaborate with any pharmaceutical partner in the development of connected therapeutics.

SHL Medical has officially opened its new, state-of-the-art manufacturing facility in North Charleston, South Carolina, marking a major milestone in its global expansion. The $220 million, fully automated site will produce SHL’s industry-leading autoinjectors—widely used in cardiometabolic, endocrine, dermatology, and musculoskeletal therapies—to meet growing global and U.S. demand.

This facility strengthens SHL’s U.S. presence, enhances supply chain resilience, and complements existing operations in Florida, Taiwan, and an upcoming site in Switzerland—making SHL the only autoinjector manufacturer operating across three continents. With over 300 local jobs created and a goal of delivering 1.5 billion devices by 2025, SHL reinforces its position as a global leader in drug delivery solutions.

The grand opening was attended by local officials and international dignitaries, celebrating SHL’s contribution to healthcare innovation and regional economic growth.

An automatic, multi-fixed-dose pen designed specifically for cardiometabolic therapies.

SHL Medical has announced a strategic partnership with Grand River Aseptic Manufacturing (GRAM) to provide fill-finish services for the RTU cartridge used in the Maggie® 5.0 mL autoinjector. This device, an extension of SHL’s 3.0 mL Maggie, is designed for large-volume drug delivery and features SHL’s Needle Isolation Technology (NIT®) for enhanced ease of use and safety.

GRAM, a specialist in sterile injectable biologics and scalable pharmaceutical manufacturing, brings deep aseptic fill-finish expertise to the collaboration. Together, SHL and GRAM will offer pharmaceutical companies an integrated solution—streamlining development, strengthening supply chains, and accelerating time-to-market for Maggie® 5.0.

Leaders from both companies highlighted the partnership’s shared commitment to innovation, patient-centered solutions, and delivering value to pharma clients and end users alike.

SHL Medical and Kindeva Drug Delivery have formed a strategic partnership to offer fill-finish and pre-validated final assembly services for SHL’s Molly® autoinjector at Kindeva’s Bridgeton and Maryland Heights facilities.

Molly®, a modular single-dose autoinjector, is designed to help pharma and biotech companies reduce upfront investment and accelerate development. The collaboration will streamline communication, simplify supply chains, and support faster project delivery.

By combining SHL’s device expertise with Kindeva’s end-to-end CDMO capabilities, the partnership aims to bring innovative therapies to patients more efficiently and effectively.

Reunite integrates two core components: a dual-chamber cartridge (DCC) and SHL Medical’s proprietary Needle Isolation Technology (NIT).

SHL Medical is now member of the Subcutaneous Drug Development & Delivery Consortium aiming to collectively address the challenges in the subcutaneous industry and actively contribute towards patients’ independence globally.   

A systemic review of Molly's integrated and flexible device design and development model.

SHL Medical and Kymanox Corporation have entered a non-exclusive strategic partnership to combine SHL’s advanced drug delivery systems with Kymanox’s expertise in combination products and professional life sciences services. The collaboration aims to streamline development, improve communication, and enhance efficiency across the drug delivery and commercialization process.

Through this partnership, SHL can recommend Kymanox as a trusted service partner, while Kymanox clients benefit from SHL’s innovative device platforms. Both companies will maintain other industry relationships, with the partnership forming part of SHL’s Alliance Management Program and Kymanox’s Preferred Partners network. Leaders from both organizations emphasized their shared commitment to patient-centric solutions, innovation, and accelerating the delivery of high-quality therapies to market.

Maggie 5.0 is a large-volume, cartridge-based autoinjector, built with our market-proven Needle Isolation Technology (NIT).

SHL Medical is proud to announce that our Elexy™ autoinjector has won the 2025 Pharmapack Awards in the Delivery and Device Innovation category. This win reinforces our commitment to innovation and excellence in the ever-evolving landscape of drug delivery industry.

Maggie is a cartridge-based autoinjector technology built with our market-proven Needle Isolation Technology (NIT).

SHL Medical is pleased to announce the release of its 2023 sustainability report, which details the company’s ongoing efforts and accomplishments in sustainability and innovation. 

Molly 2.25 is a large-volume variant of the Molly autoinjector, developed to support the delivery of larger-volume biologics with the same 2-step operation.

SHL Medical and AARDEX Group announced their strategic partnership aimed at delivering an end-to-end solution for pharma customers seeking to demonstrate patient adherence within clinical trials.

Molly is a single-dose, pre-filled syringe based-autoinjector, developed to reduce initial investments and expedite development timelines.

SHL Medical and AARDEX Group announced their strategic partnership aimed at delivering an end-to-end solution for pharma customers seeking to demonstrate patient adherence within clinical trials.

The report provides a comprehensive overview of our ongoing efforts, achievements, and strategic priorities in sustainability and innovation.

SHL Medical announced today the release of its Sustainability Report for 2022. The report provides a comprehensive overview of the company’s efforts to promote sustainability and outlines its commitment to a sustainable future.

At Pharmapack 2026, SHL Medical will unveil its latest innovation: a next-generation automatic multi-fixed-dose pen designed specifically for the rapidly expanding cardiometabolic therapeutics market.
This innovative new product directly addresses needs of biopharma companies launching new weight management drugs, where market differentiation and patient compliance are key.
The pen delivers multiple pre-set doses in a single device, eliminating the risk of dosing errors, thereby meeting critical industry demands for safety and patient-centricity. It utilizes RTU cartridges, which results in streamlined pharma operations, and - through minimizing labeling, packaging, and distribution needs - it delivers substantial sustainability and cost efficiencies.
SHL's mission is to empower patients’ independence. Leveraging decades of expertise, SHL enables home-based treatments that are safer, simpler, and more economical, driving better outcomes for patients and partners alike. Join us to experience the future of weight management drug delivery redefined.

SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider. The acquisition is SHL Medical’s response to the growing market demand for drug delivery solutions and will support its manufacturing operations globally, especially the upcoming Swiss manufacturing site in Zug.  

Experience how SHL Medical's Reunite autoinjector automates the reconstitution of lyophilized drugs. Featuring a dual-chamber cartridge system and our market-proven Needle Isolation Technology (NIT), Reunite enables a simple three-step operation to support patient safety and deliver reliable self-injection of complex formulations.

SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, to develop an autoinjector for clinical and potential commercial supply of MoonLake’s Nanobody® sonelokimab based on SHL Medical’s Molly® autoinjector technology.

SHL Medical embarked on a journey of transformation with the Molly autoinjector. After successfully supporting the development of more than a dozen combination products globally, we decide to take the innovation up a notch. This is the next generation of Molly and Molly 2.25. Built upon a modular platform technology, Molly offers flexibility beyond a conventional platform model that spans across the development processes.

Continuing its ambitious growth journey, SHL Medical has acquired Superior Tooling Inc., a US-based manufacturing company specializing in plastic injection molds. The integration of Superior Tooling will strengthen the SHL’s inhouse manufacturing capabilities, particularly for its upcoming US manufacturing site in North Charleston, SC, scheduled to begin operations in mid-2024.

Elexy is a versatile, electromechanical autoinjector that features a reusable power unit compatible with drug cassettes containing a pre-filled syringe or a cartridge. Its versatility enables a wider choice of intended injection profiles, including drug volume, drug viscosity, and injection speed. In addition, Elexy features connectivity to collect comprehensive injection-related data.

SHL Medical, a leading provider of drug delivery solutions worldwide, furthers its expansion strategy by acquiring SMC Mould Innovation, a Swiss manufacturer specialising in high-performance injection molding tools, based in Hallau. 

The constant evolution of drug formulations across various disease areas opens a wider avenue for subcutaneous drug delivery. Built with the market-proven Needle Isolation Technology (NIT), SHL Medical's Maggie autoinjectors accommodate varying formulations with volumes up to 5.0 mL. 

SHL Medical, a world-leading provider of drug delivery devices, and ten23 health®, a leading Swiss Contract Development and Manufacturing Organization (CDMO) for sterile drugs, announced strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.

Quanta pen injector is developed for once-weekly cardiometabolic therapies. It integrates an automatic mechanism with a fixed, multi-dose configuration, offering 4-6 doses in a single device.

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. 

Go behind the scenes to discover how an autoinjector is made—from initial design and precision engineering to large-scale manufacturing and quality assurance. See how SHL Medical brings drug delivery innovation to life.

SHL Medical (SHL), a world-leading solutions provider of advanced drug delivery systems enters a non-exclusive strategic partnership agreement with FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies and oncolytic viruses to help meet growing market demand for autoinjector medicines.

Reunite is an innovative, three-step, dual-chamber cartridge autoinjector, built with our market-proven Needle isolation Technology (NIT), designed to support automated reconstitution and delivery of lyophilized formulations.
It is the only mechanical autoinjector of its kind to be available on the market. It was granted marketing authorization in the US in 2024, and in the EU, UK, and Switzerland in 2025. Reunite features a simple, three-step process: unlock, twist, push, ensuring accurate dosing with a user-friendly design for safe and effortless use.

SHL Medical, a world-leading provider of advanced drug delivery solutions, is a proud recipient of the prestigious EcoVadis® Silver Medal for its sustainability performance. The company received further recognition from the Science Based Targets initiative (SBTi) for its near-term emissions targets.

Discover how an autoinjector is made, from initial design and precision engineering to large-scale manufacturing and quality assurance. See how SHL Medical brings drug delivery innovation to life.

The partnership between SHL Medical and Lifecore Biomedical will allow the companies to exchange knowledge and experience in their respective fields and provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.

As labor costs and demand for autoinjectors rise, a fully automated assembly machine with the flexibility to produce smaller batches has quickly become the much-needed solution. SHL’s SMART is pioneering the path to address this need with its ability to combine the flexibility of manual processes with the efficiency and reliability of automated systems. Its modular design combines physical components with digital controls for versatile assembly and efficient project changeovers.

SHL Medical is forging alliances with a selection of solutions providers along the drug delivery value chain, including with primary container providers, CMOs/CDMOs, and various service providers and suppliers of primary and secondary packaging, to further strengthen its vertically integrated business model.

Meet SLIM (SMART-Line Integrated Measurement), our state-of-the-art technology designed to replicate critical assembly steps in a lab environment. With the ability to process both sub-assembly and final assembly on the same equipment, SLIM supports multiple device variations, making it ideal for development, clinical, and low-volume commercial production. It’s a perfect example of how we integrate advanced technology to enhance flexibility and efficiency in our development processes.

In this webinar, the speakers will help you understand the intricacies of digitalization in autoinjector manufacturing, reporting on the key learnings from implementing end-to-end digital processes – from product and process development down to the shop floor and machine monitory systems.

SHL Medical's automation systems department develops advanced assembly machines, allowing us to offer fully automated solutions for rigorous testing and production needs. Our in-house fully automated assembly machine offers the reliability to produce high-volume productions with identical quality from the first assembled unit until the last unit.

Environmental impact is an area of increasing focus for the pharma and biopharma industries, with companies like Merck, Pfizer and GlaxoSmithKline setting ambitious targets for carbon neutrality and laying plans for waste reduction.   

SHL Medical offers final assembly, labeling, and packaging services for drug delivery devices. We have a modern facility with expanding competencies, an industry first-in-class site that provides final assembly equipment qualification, process development, design transfer, and turnkey final assembly services. The facility is further equipped with device labeling, carton packaging, and serialization capabilities, providing an end-to-end solution for final combination products.

SHL Medical and Innovation Zed have announced plans to launch InsulCheck® DOSE in 2022.

SHL Medical has established a strong presence across continents, strategically expanding our facilities to meet the growing demands of autoinjector industry. From the Americas to Asia to Europe, our global network allows us to deliver consistent quality and innovation, no matter where we are. Each location plays a vital role in our mission to improve patient care, offering local expertise while contributing to our global vision. 

This white paper is a retrospective analysis on how the new generation of Molly autoinjectors have incorporated a greater level of flexibility in its design and development model.

SHL Medical announced the launch of its Molly autoinjector webpage.

SHL’s Molly® and Molly® 2.25 mL autoinjectors are built upon a proven modular platform technology to support shorter development timelines and increased flexibility in device design and production.